Swiss National Bank Makes New $1.01 Million Investment in Tyra Biosciences, Inc. $TYRA

Swiss National Bank bought a new stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 26,400 shares of the company’s stock, valued at approximately $1,011,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Jennison Associates LLC bought a new position in shares of Tyra Biosciences during the first quarter worth about $24,222,000. Bank of New York Mellon Corp lifted its position in Tyra Biosciences by 18.6% in the 1st quarter. Bank of New York Mellon Corp now owns 72,213 shares of the company’s stock valued at $2,766,000 after purchasing an additional 11,312 shares during the last quarter. Strs Ohio boosted its stake in Tyra Biosciences by 2,485.7% during the 1st quarter. Strs Ohio now owns 18,100 shares of the company’s stock valued at $693,000 after purchasing an additional 17,400 shares during the period. Hilton Head Capital Partners LLC bought a new position in Tyra Biosciences in the 1st quarter worth about $30,000. Finally, SG Americas Securities LLC bought a new position in Tyra Biosciences in the 1st quarter worth about $276,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Trading Down 3.6%

Shares of NASDAQ:TYRA opened at $31.88 on Friday. The company has a 50 day moving average of $30.48 and a 200-day moving average of $32.66. The firm has a market cap of $1.90 billion, a P/E ratio of -14.62 and a beta of 0.76. Tyra Biosciences, Inc. has a twelve month low of $9.96 and a twelve month high of $40.65.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Equities research analysts forecast that Tyra Biosciences, Inc. will post -2.68 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TYRA shares. Canaccord Genuity Group initiated coverage on Tyra Biosciences in a report on Monday, April 6th. They set a “buy” rating and a $50.00 price target on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Bank of America raised their target price on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. JonesTrading assumed coverage on Tyra Biosciences in a research note on Wednesday, June 17th. They set a “buy” rating and a $56.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price target on shares of Tyra Biosciences in a research report on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Tyra Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.